Editorial

July 31, 2023


This Month’s Issue of JUO
Cheol Kwak
J Urol Oncol. 2023;21(2):95-96.

Invited Review

July 31, 2023


The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
Chang Wook Jeong
J Urol Oncol. 2023;21(2):97-105.

Invited Review

July 31, 2023


Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Byung Kwan Park
J Urol Oncol. 2023;21(2):106-111.

Topic Article

July 31, 2023


Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer
Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al.
J Urol Oncol. 2023;21(2):112-120.

Original Article

July 31, 2023


A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening
Jung Sik Huh, Kyung Kgi Park
J Urol Oncol. 2023;21(2):121-127.

Invited Review

July 31, 2023


Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyunho Han, Minyong Kang, Seok-Soo Byun, et al.
J Urol Oncol. 2023;21(2):128-139.

Invited Review

July 31, 2023


Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery?
Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al.
J Urol Oncol. 2023;21(2):140-147.

Original Article

July 31, 2023


Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma
Dongsu Kim, Bumjin Lim, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):148-153.

Invited Review

July 31, 2023


The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Sang Hun Song, Jong Jin Oh
J Urol Oncol. 2023;21(2):154-164.

Original Article

July 31, 2023


Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al.
J Urol Oncol. 2023;21(2):165-173.

Original Article

July 31, 2023


The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma
Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):174-180.

This Month’s Issue of JUO
Cheol Kwak
J Urol Oncol. 2023;21(2):95-96.

Editorial

Jul 31, 2023

The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
Chang Wook Jeong
J Urol Oncol. 2023;21(2):97-105.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Byung Kwan Park
J Urol Oncol. 2023;21(2):106-111.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer
Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al.
J Urol Oncol. 2023;21(2):112-120.

Topic Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening
Jung Sik Huh, Kyung Kgi Park
J Urol Oncol. 2023;21(2):121-127.

Original Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyunho Han, Minyong Kang, Seok-Soo Byun, et al.
J Urol Oncol. 2023;21(2):128-139.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery?
Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al.
J Urol Oncol. 2023;21(2):140-147.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma
Dongsu Kim, Bumjin Lim, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):148-153.

Original Article

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Sang Hun Song, Jong Jin Oh
J Urol Oncol. 2023;21(2):154-164.

Invited Review

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al.
J Urol Oncol. 2023;21(2):165-173.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma
Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):174-180.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043


Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org                

Copyright © The Korean Urological Oncology Society.

Developed in M2PI